Ipsavent 25 mg Respirator Solution is intended for oral inhalation via a nebulizer. It must not be swallowed or injected. The solution may need to be diluted with normal saline before use, depending on the prescribed dose and the nebulizer device. Follow the instructions provided with your nebulizer and as directed by your physician.

Ipratropium Bromide is an anticholinergic (parasympatholytic) agent that blocks muscarinic cholinergic receptors in the bronchial smooth muscle. This inhibition of acetylcholine's action prevents the increase in intracellular cyclic guanosine monophosphate (cGMP) levels caused by the interaction of acetylcholine with muscarinic receptors, leading to bronchodilation. It primarily works locally on the airways.

• •Hypersensitivity to Ipratropium Bromide, atropine or its derivatives (e.g., Atrovent, Combivent components).
• •Patients with allergies to soy lecithin or related food products (e.g., soybean, peanuts) if the formulation contains these.

Store below 30°C. Protect from light and moisture. Do not freeze. Keep out of reach of children.

Symptoms of overdose are typically mild and include dry mouth, blurred vision, and slight tachycardia. Management is generally supportive and symptomatic. Severe anticholinergic effects are unlikely due to poor systemic absorption.

Pregnancy Category B. Studies in animals have not shown harm to the fetus, but human data is limited. Use during pregnancy only if clearly needed. It is not known whether Ipratropium Bromide is excreted in human milk; use with caution in nursing mothers.